BiosanaPharma Sees Success In Omalizumab Trial
Phase I Study Shows Favorable Comparison To Novartis' Xolair Brand
BiosanaPharma has revealed success in a comparative Phase I trial for its BP001 omalizumab proposed biosimilar rival to Novartis’ Xolair.
You may also be interested in...
Biosimilars major Celltrion has announced further progress on its biosimilar Xolair candidate, as it faces off against the likes of Glenmark to introduce global competition to Genentech/Novartis’ blockbuster cardiovascular biologic.
Glenmark appears close to sewing up a deal for its biosimilar version of Novartis/Genentech's Xolair amid the firm's ongoing focus on partnering out some key assets. It also expects to kick off plans to raise capital in the US for its innovation business in Q4 of fiscal 2019-20.
Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essexor biosimilar bevacizumab to treat ophthalmic diseases.